Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686842 · ClinicalTrials.gov registry record · Phase 1
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00686842: Clinical Trial Phase 1 study, sponsored by AIDS Malignancy Consortium.
NCT00686842 is a Phase 1 study that was terminated before completion, run by AIDS Malignancy Consortium. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686842, a Phase 1 study, was terminated before completion, sponsored by AIDS Malignancy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.
Primary Outcome
Patients who experienced an adverse event of grade 3 or greater
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- GENETIC polymerase chain reaction
- OTHER immunohistochemistry staining method
- DRUG VEGF inhibitor PTC299
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Why NCT00686842 stopped before completion
NCT00686842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00686842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00686842 about?
NCT00686842 is a clinical study titled "PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma". RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.
What is the current status of trial NCT00686842?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00686842?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), polymerase chain reaction (GENETIC), immunohistochemistry staining method (OTHER), VEGF inhibitor PTC299 (DRUG).
Who is sponsoring clinical trial NCT00686842?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00686842's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia